PharmaPoint:偏頭痛 - 日本的醫藥品的預測與市場分析
PharmaPoint: Migraine - Japan Drug Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 114 Pages
|PharmaPoint:偏頭痛 - 日本的醫藥品的預測與市場分析 PharmaPoint: Migraine - Japan Drug Forecast and Market Analysis to 2023|
|出版日期: 2014年03月31日||內容資訊: 英文 114 Pages||
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
The launch of drugs in the Japanese market is often delayed due to the requirement by Japanese regulatory agencies to perform clinical studies in Japanese patients; as a result, the market uptake of lasmiditan and MK-1602 will occur at the very end of the forecast period, when they are expected to steal shares from triptans as well as gaining additional patient share from the underserved population.